A panel of medical experts recommended in January 2016 that the Food and Drug Administration approve a new way of treating opiate addiction and on May 26, 2016, the FDA announced approval for the first buprenorphine implant for the treatment of opioid dependence.
Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months using a slender rod implant for patients already stable on the medication. Opioid dependence is currently a major public health epidemic and has taken a devastating toll on American families. The hope is that the implant will not only curb the problem of the illegal use and sale of buprenorphine but will also help with the accidental overdoses of children who ingest the drug. Emergency department visits involving illicit use of buprenorphine more than tripled from 2006 to 2010. Probuphine should be used as part of a complete treatment program that includes counseling and the support that treatment provides.
New Bridge Foundation® provides clinical services for opioid addiction. Please contact us at 1-(866) 772-8491 if you or a loved one would like a free assessment.
